Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia

作     者：Pankaj Singh Anant Indaram Ronald Greenberg Vernu Visvalingam Simmy Bank 

作者机构：Division of GastroenterologyAlbert Einstein Colege of MedicineLong Island Jewish Medical CenterNew Hyde ParkNew York 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2000年第6卷第6期

页      面：789-792页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：gastroesophageal reflux proton pump inhibitors enterochromaffin cell hypergastrinemia carcinoid tumor biopsy 

摘      要：AIM To evaluate the long-term safety ofomeprazole in patients of gastroesophagealreflux disease resistant to treatment with H2receptor *** We prospectively followed 33patients on omeprazole therapy for severeerosive esophagitis for 5-8 years,with periodicgastrin levels,*** infection,gastricbiopsies for incidence of ECL cell hyperplasia,carcinoids,gastric atrophy and *** 185 patient follow-up years and 137 gastricbiopsies were *** Among the 33 patients,36% reachedtheir peak gastrin levels in an average of 8months to one year,then drifted Down slowlyover 1-2 year period to just above their baselinelevel,24% of the patients had a peak gastrinlevel above 400ng·L^1 and one patient had apeak level above 1000 ng·L^*** patient had amild ECL cell hyperplasia which was self limitingand did not show any dysplastic *** percent of patients were positive *** *** gastric biopsies did notshow gastric atrophy,intestinal metaplasia orneoplastic *** In a series of 33 patients followed for 5 - 8 years on omeprazole therapy for severe reflux esophagitis, we did not observe any evidence of significant ECL cell hyperplasia, gastric atrophy, intestinal metaplasia, dysplasia or neoplastic changes.